conference agenda · 2020. 12. 4. · dr. muhammad azrif inaugural address 12:00 - 14:00...

Conference Agenda

th th5 & 6 December 2020

MalaysiaMalaysia

In collaboration withPresented by

www.bestofoncology.org

Best of ASCO 2020, Malaysia has been awarded16 CPD points by Academy of Medicine of Malaysia

Conference Agenda

DAY-1 | 5th December 2020 | 11:55 - 18:55 | Malaysian TimeTime Session Type Speaker Name Moderator Title of Presentation

11:55 Presidential AddressDr. Muhammad Azrif Inaugural address

12:00 - 14:00 Pre-Conference Workshop - From Bench-to-Bedside: The Role of Biomarkers in Immunotherapy

12:00 - 12:05 MSD MasterClassDr. Azura Rozila Ahmad Welcome & Opening Remarks

12:05 - 12:40MSD MasterClass with Q&A

Dr. Pathmanathan Rajadurai

Dr. Azura Rozila Ahmad

Biomarker on the horizon & science behind the biomarker


Dr. Nuttapong Ngamphaiboon


Value of PD-L1 testing for H&N cancer IO treatment



Value of PD-L1 testing for NSCLC cancer IO treatment

13:50 - 13:55 MSD MasterClassDr. Azura Rozila Ahmad Question & Answer Session

13:55 - 14:00 MSD MasterClassDr. Azura Rozila Ahmad Closing Remarks

14:05 - 14:45 Session 1 - Breast Cancer - Local / Regional / Adjuvant

14:05 - 14:10 Presentation Dr. Seema Khan

A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108).

14:10 - 14:15 Presentation Dr. Jennifer Leong

Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (TDM1) pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high- risk HER2-positive early breast cancer (EBC).

14:15 - 14:20 Presentation Dr. Cynthia Ma

ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2- negative breast cancer (ER+HER2- BC) in postmenopausal (PM) women: Alliance A011106.

14:20 - 14:25 Presentation Dr. Ishita Laroiya

MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients.

14:30 - 14:45Panel Discussion & Q&A

Dr. Cynthia Ma

Dr. Aqilah Othman

Dr. Jennifer Leong

Dr. Ishita Laroiya

Scientific Programme


14:50 - 15:30 Session 2 - Breast Cancer - Metastatic

14:50 - 14:55 Presentation Dr. Javier Cortes

Randomized, double-blind, phase III study of pembrolizumab+ chemotherapy versus placebo + chemotherapy in recurrent inoperable or metastatic triple-negative breast cancer

14:55 - 15:00 Presentation Dr. Hafizah Zaharah

A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded).

15:00 - 15:05 Presentation Dr. Mastura Md Yusof

MONARCH 2: subgroup analysis of patients receiving abemaciclib + fulvestrant as first- and second-line therapy for HR+, HER2- advanced breast cancer

15:05 - 15:10 Presentation Dr. Vaishnavi Jeyasingam

PARSIFAL: A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER)[+]/HER2[-] metastatic breast cancer

Quick Quiz 1


Dr. Javier Cortes

Dr. Ang Soo Fan

Dr. Mastura Md Yusof

Dr. Vaishnavi Jeyasingam

15:35 - 15:55Sponsored Session by Zuellig Pharma

Dr. Antonio Lumbart Cussac

CDK4/6 Inhibitor in the Management of Metastatic Breast Cancer: Are they all the same?

15:55 - 16:10 Exhibition Tour Break

16:10 - 16:20 Session 3 - Melanoma / Skin Cancers

16:10 - 16:15 Presentation Dr. Amod Sarnaik

Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies.

16:15 - 16:20 Presentation Dr. Shivam Verma

Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression on PD1 Ab in melanoma (MEL) in a phase II trial.

16:25 - 16:35 Session 4 - Cancer Prevention, Risk Reduction and Genetics

16:25 - 16:30 Presentation Dr. Ho Gwo Fuang

Results from MAGENTA: A national randomized four-arm noninferiority trial evaluating pre- and post-test genetic counselling during online testing for breast and ovarian cancer genetic risk.

16:30 - 16:35 Presentation Dr. Aqilah Binti Othman

Uptake of oophorectomy in women with findings on multigene panel testing: Results from the Prospective Registry of Multiplex Testing (PROMPT).


16:40 - 16:45 Session 5 - Sarcoma

16:40 - 16:45 Presentation

Dr. Hadi B. Jalil

Comparison of two chemotherapy regimens in Ewing sarcoma (ES): Overall and subgroup results of the Euro Ewing 2012 randomized trial (EE2012).

Quick Quiz 2

16:50 - 17:00 Session 6 - Central Nervous System Tumors

16:50 - 16:55 Presentation Dr. Jennifer Leong

Randomized phase III study of high-dose methotrexate and whole brain radiotherapy with or without concomitant and adjuvant temozolomide in patients with newly diagnosed primary central nervous system lymphoma: JCOG1114C.

16:55 - 17:00 Presentation Dr. Hafizah Zaharah

Long-Term Analysis of the WHO-Defined Molecular Subgroups of High-Risk Grade II Gliomas Treated with Radiation and Temozolomide on NRG Oncology/RTOG 0424

17:05 - 17:15 Session 7 - Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

17:05 - 17:10 Presentation Dr. Lim Yueh Ni

Safety and efficacy of pyrotinib in patients with NSCLC and other advanced solid tumors with activating HER2 alterations: A phase I basket trial

17:10 - 17:15 Presentation Dr. Chandan Das

Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced solid tumors: Updated results from a phase Ib-II trial

Quick Quiz 3


17:30 - 17:40 Session 8 - Gastrointestinal Cancer—Colorectal and Anal

17:30 - 17:35 Presentation Dr. Salvatore Siena

A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.

17:35 - 17:40 Presentation Dr. Alberto F. Sobrero

Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration.

17:45 - 18:15 Session 9 - Gastrointestinal Cancer—Gastroesophageal, Pancreatic and Hepatobiliary

17:45 - 17:50 Presentation Dr. Tan Chih Kiang

Efficacy, Tolerability and Biologic Activity of a Novel Regimen of Tremelimumab (T) in Combination with Durvalumab (D) for Patients (pts) with Advanced Hepatocellular Carcinoma (aHCC).

17:50 - 17:55 Presentation Dr. Junie Khoo YY

Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 study

Quick Quiz 4



18:15 - 18:35 Session 10 - Genitourinary Cancer—Kidney and Bladder

18:15 - 18:20 Presentation Dr. Adlinda Alip

Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.

18:20 - 18:25 Presentation Dr. Maha H.A. Hussain

IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC).

18:25 - 18:30 Presentation Dr. Wong Yoke Fui

Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.

18:30 - 18:35 Presentation Dr. Michael Atkins

Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260).

18:40 - 18:55 Quiz Session 1


DAY - 2 | 6th December 2020 | 10:55 - 17:30 | Malaysian TimeTime Session Type Speaker Name Moderator Title of Presentation

10:55 Presidential AddressDr. Muhammad Azrif Welcome Address

11:00 - 11:40 Session 11 - Genitourinary Cancer—Prostate, Testicular and Penile

11:00 - 11:05 Presentation Dr. Teng Aik Ong

Final overall survival (OS) from PROSPER: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC).

11:05 - 11:10 Presentation Dr. Aditya P. Sharma

Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC).

11:10 - 11:15 Presentation Dr. Kalpesh Parmar

Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).

11:15 - 11:20 Presentation Dr. Cheah Soon Keat

Impact of PSMA-targeted imaging with 18F-DCFPyL-PET/CT on clinical management of patients (pts) with biochemically recurrent (BCR) prostate cancer (PCa): Results from a phase III, prospective, multicenter study (CONDOR).

Quick Quiz 1


Dr. Cheah Soon Keat

Dr. Junie Khoo YY

Dr. Teng Aik Ong

Dr. Kalpesh Parmar

Dr. Aditya P. Sharma

11:45 - 12:20 Session 12 - Lung Cancer - Non-Small Cell Metastatic

11:45 - 11:50 Presentation Dr. Navneet Singh

Final analysis of KEYNOTE-189: Pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro) in patients (pts) with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC)

11:50 - 11:55 Presentation Dr. Tan Chih Kiang

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01.


Dr. Makoto Maemendo

Final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations.

Quick Quiz 2



Dr. Tan Chih Kiang

Dr. Liam Chong Kin

Dr. Navneet Singh

12:25 - 13:00 Session 13 - Gynecologic Cancer

12:25 - 12:30 Presentation Dr. Hafizah Zaharah Binti Ahmad

Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.

12:30 - 12:35 Presentation Dr. Rozita Abdu Malik

A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer.

12:35 - 12:40 Presentation Dr. Bhavana Rai

Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20

12:40 - 12:45 Presentation Dr. Aashima AroraLong-term oncological safety of sentinel lymph node biopsy in early-stage cervical cancer.

Quick Quiz 3


Dr. Aashima Arora

Dr. S. C. Saha

Dr. Bhavana Rai

13:10 - 13:40 Session 14 - Head and Neck Cancer

13:10 - 13:15 Presentation Dr. Wan Zamaniah Wan Ishak

KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

13:15 - 13:20 Presentation Dr. Naomi Kiyota

Phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck (JCOG1008).

13:20 - 13:25 Presentation Dr. Bhumsuk KeamRandomized phase II study of axitinib versus observation in patients with recurred or metastatic adenoid cystic carcinoma.

13:25 - 13:30 Presentation Dr. Robert Ferris

Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3311)

Quick Quiz 4


Dr. Naomi KiyotaDr. Divya Khosla

Dr. Wan Zamaniah Wan Ishak



14:00 - 14:35 Session 15 - Hematologic Malignancies - Leukemia, MDS and Allotransplant

14:00 - 14:05 Presentation Dr. Hany Haqimi Wan Hanafi

Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies.


Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant-IDH2 (mIDH2) newly diagnosed acute myeloid leukemia (ND-AML).


Interim analysis (IA) of OPTIC: A dose-ranging study of three ponatinib (PON) starting doses.


Updated Results from Phase I Dose-Escalation Study of AMG 330, a Bispecific T-Cell Engager Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML).


Dr. Hany Haqimi Wan Hanafi

Dr. Azlan Husin

14:40 - 15:10 Session 16 - Hematologic Malignancies - Lymphoma and CLL

14:40 - 14:45 Presentation Dr. John G. Kuruvilla

Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL).

14:45 - 14:50 Presentation Dr. Ganesh Kasinathan

ASPEN: Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM).


Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL).


A multicenter phase II study of venetoclax plus dose-adjusted R-EPOCH (VR-EPOCH) for Richter’s syndrome.


Dr. Ganesh Kasinathan

Dr. Lau Ngee Siang

15:15 - 15:55 Session 17 - Hematologic Malignancies-Plasma Cell Dyscrasia

15:15 - 15:20 Presentation Dr. Shaji Kumar

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.

15:20 - 15:25 Presentation Dr. Nur Adila Bt Anuar

Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.



Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: Initial results of the phase III BOSTON study.


Phase I Study of Teclistamab, a Humanized B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma (R/R MM)


Dr. Nur Adila Bt Anuar

Dr. Haris Abdul Rahman


16:10 - 17:10 Session 18 - Lung Cancer - Non-Small Cell Local-Regional/Small Cell/Other

16:10 - 16:15 Presentation Dr. Roy S. Herbst

Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.


Dr. Tang Weng Heng

Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated Results from the phase III CASPIAN study.

16:20 - 16:25 Presentation Dr. Hye Ryun Kim

Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC).

16:25 - 16:30 Presentation Dr. Yi-Long Wu

Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation-Final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial.


Dr. Roy S. Herbst Dr. Jennifer Leong

16:50 - 17:05 Quiz Session 2

17:10 Onwards Valedictory & Awards’ Declaration

Support Desk

90306 95668 | 81306 06116 | 88006 91399 | 86555 64901


MalaysiaMalaysia

In collaboration with

Presented by


LEADERBOARDAWARDS&

SPONSORED BY

®Best of ASCO ASCO2020Virtual Conference a program licensed

by the American Society of Clinical Oncology, Inc.


LEADERBOARD!How to achieve points on Leaderboard ?

Log-inAttending each

sessionEach correctquiz answer

Visiting eachexhibitor stall

Downloading documents

from each exhibitor stall

Submitting completefeedback form

Watching videoat each exhibitor stall

100 PTS

10 PTS 10 PTS

20 PTS

10 PTS

10 PTS 10 PTS

th th th5 , 6 & 7 Position

EXCITING PRIZES TO BE WON VIA LEADERBOARD

st nd1 & 2 Position 3rd th & 4 PositionDigital Access to

ASCO20 Videos and SlidesDigital Access to IO Symposium

Videos and SlidesDigital Access to

2020 Educational Book

Winners will be declared in the end of the Conference (Approx. 17:00 – 17:30)thon Day 2, 6 December, 2020.


3rd PositionDigital Access to 2020 Educational Book

nd 2 PositionDigital Access to IO Symposium

Videos and Slides

st1 PositionDigital Access to

ASCO20 Videos and Slides

ASK YOURBEST QUESTIONS

AND WIN EXICITING AWARDS

SPONSORED BY

®Best of ASCO ASCO2020Virtual Conference a program licensed

by the American Society of Clinical Oncology, Inc.


Winners will be declared in the end of the Conference (Approx. 17:00 – 17:30)thon Day 2, 6 December, 2020.

Mr./Ms. Cross Examiner will be awarded to delegates who will dropmost relevant questions in the Q&A box during each session.

ASK RELEVENT QUESTIONS DURING THE CONFERENCE ANDSTAND A CHANCE TO WIN AWARDS SPONSORED BY ASCO

MR./MS. CROSS EXAMINER


Patron Partner

Diamond Partner

Gold Partner

Exhibitor

Thank you Partners


MAKING MORETOMORROWSPOSSIBLE FOR PATIENTS

For Healthcare Professionals Only

Before prescribing KEYTRUDA®, please read the Local Product Circular.

Copyright© 2020 Merck Sharp & Dohme (M) Sdn. Bhd., a subsidiaryof Merck & Co., Inc., Kenilworth, NJ, USA. All rights reserved.MY-KEY-00431 Nov/2020

Actor portra

yal. Not an

actual patie

nt

References: 1. Garon EB, et al. 5-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. J Clin Oncol 37. Presented at ASCO 2019. 2. Brahmer JR, et al. KEYNOTE-024 5-year OS update: first-line pembrolizumab vs platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer and PD-L1 tumor proportion score ≥50%. Presented at Virtual ESMO 2020.

mNSCLC patients have the chance to survive 5 years1,2Almost

23.2%29.6%

PD-L1 TPS≥50%

31.9%

5-Year OS1,2

PD-L1 TPS≥1%PD-L1 TPS≥50%

KEYNOTE-024

Scan the QR code to access theSelected Safety Information

KEYNOTE-001

Treatment-Naive PatientsTreatment-Naive PatientsTreatment-Naive Patients

Support Desk

90306 95668 | 81306 06116 | 88006 91399 | 86555 64901


MalaysiaMalaysia

In collaboration with

Presented by


conference agenda · 2020. 12. 4. · dr. muhammad azrif inaugural address 12:00 - 14:00...

Documents